23,395 Shares in Charles River Laboratories International, Inc. (NYSE:CRL) Purchased by Pekin Hardy Strauss Inc.

Pekin Hardy Strauss Inc. bought a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the 1st quarter, according to its most recent 13F filing with the SEC. The firm bought 23,395 shares of the medical research company's stock, valued at approximately $3,521,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Charles River Laboratories International by 15.4% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,118 shares of the medical research company's stock valued at $952,000 after purchasing an additional 817 shares during the last quarter. Janney Montgomery Scott LLC grew its holdings in Charles River Laboratories International by 13.1% during the 1st quarter. Janney Montgomery Scott LLC now owns 44,500 shares of the medical research company's stock valued at $6,698,000 after buying an additional 5,148 shares during the last quarter. GAMMA Investing LLC increased its position in Charles River Laboratories International by 61.6% during the first quarter. GAMMA Investing LLC now owns 1,398 shares of the medical research company's stock worth $210,000 after buying an additional 533 shares in the last quarter. Blue Trust Inc. raised its holdings in shares of Charles River Laboratories International by 60.1% in the first quarter. Blue Trust Inc. now owns 2,407 shares of the medical research company's stock worth $362,000 after acquiring an additional 904 shares during the last quarter. Finally, Smartleaf Asset Management LLC lifted its position in shares of Charles River Laboratories International by 61.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 459 shares of the medical research company's stock valued at $84,000 after acquiring an additional 175 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.

Insider Transactions at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 500 shares of the business's stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total transaction of $72,705.00. Following the transaction, the executive vice president directly owned 19,513 shares of the company's stock, valued at approximately $2,837,385.33. The trade was a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.30% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several brokerages recently weighed in on CRL. Robert W. Baird boosted their target price on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the company a "neutral" rating in a research note on Thursday, May 8th. Mizuho lowered their target price on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a research note on Wednesday, April 9th. Barclays increased their price target on Charles River Laboratories International from $145.00 to $155.00 and gave the stock an "equal weight" rating in a research note on Thursday, May 8th. Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating in a research report on Wednesday, May 14th. Finally, Wall Street Zen lowered Charles River Laboratories International from a "buy" rating to a "hold" rating in a research note on Saturday. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $171.85.

Charles River Laboratories International Stock Down 2.0%

Charles River Laboratories International stock traded down $3.19 during trading on Monday, reaching $153.93. 782,869 shares of the company's stock were exchanged, compared to its average volume of 1,028,161. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $254.15. The firm has a market cap of $7.56 billion, a price-to-earnings ratio of -236.82, a PEG ratio of 5.32 and a beta of 1.49. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.16 and a current ratio of 1.43. The company's 50-day moving average is $140.70 and its two-hundred day moving average is $152.30.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, topping the consensus estimate of $2.06 by $0.28. The company had revenue of $984.17 million during the quarter, compared to the consensus estimate of $942.34 million. Charles River Laboratories International had a positive return on equity of 15.19% and a negative net margin of 0.66%. The company's revenue was down 2.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.27 earnings per share. On average, analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).